Trobalt (retigabine)
- Region
- 🇪🇺 EU
- Active substance
- retigabine
- Company
- Glaxo Group Limited
- Status
- Withdrawn
- Therapeutic area
- Epilepsy
- EU approval
- Sun 27 Mar 2011
- Application
- EMEA/H/C/001245
- ATC
- N03AX21
- Official record
- www.ema.europa.eu
Indication
Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
Regulatory milestones
No milestones recorded in the last year.
Follow Trobalt
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.